Denis Chem Lab News

Denis Chem Lab Q3FY26 Results: Profit Surges 88.6%

Denis Chem Lab Limited reported strong Q3FY26 performance with net profit rising 88.6% to ₹332.16 lakh and revenue growing 6.2% to ₹4,551.83 lakh compared to Q3FY25.

Denis Chem Lab Limited Shareholders Approve All Six Resolutions at 44th AGM

Denis Chem Lab Limited held its 44th Annual General Meeting on September 26, 2025, through video conferencing. All six resolutions were approved by shareholders with overwhelming support ranging from 99.96% to 99.97%. Key approvals included adoption of audited financial statements for the year ended March 31, 2025, declaration of Rs. 1.50 dividend per equity share, re-appointment of Mr. Dinesh B. Patel as director, approval of cost auditor remuneration, appointment of secretarial auditors for five years (2025-26 to 2029-30), and continuation of Mr. Dinesh B. Patel as Non-Executive Director despite being 91 years old. The voting was conducted through remote e-voting from September 23-25, 2025, and e-voting during the meeting. Kashyap R. Mehta & Partners served as scrutineer for the voting process.

Denis Chem Lab Reports 19% Rise in Quarterly Profit to Rs 247.50 Lakhs

Denis Chem Lab Limited reported a net profit of Rs 247.50 lakhs for the quarter ended June 30, 2025, compared to Rs 207.63 lakhs in the same period last year, marking a 19% increase. Revenue from operations grew to Rs 4,327.59 lakhs from Rs 4,125.74 lakhs year-over-year. The company's earnings per share improved to Rs 1.78 from Rs 1.50 in the corresponding quarter of the previous year. Total expenses increased to Rs 4,026.10 lakhs, with cost of materials consumed rising to Rs 2,270.62 lakhs. The pharmaceutical company, which manufactures parenteral products including transfusion solutions in bottles, operates as a single-segment business with no subsidiaries. The board meeting was held on August 13, 2025, where directors approved the unaudited financial results.